

All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan



Elvitegravir (Vitekta[®]) film-coated tablets

Gilead Sciences Ltd

February 2014

Statement of Advice

In the absence of a submission from the holder of the marketing authorisation, elvitegravir (Vitekta[®]), co-administered with ritonavir-boosted protease inhibitor and with other antiretroviral agents, cannot be endorsed for use within NHS Wales for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.

This product is currently not marketed in the UK.

Advice context:

The All Wales Medicines Strategy Group (AWMSG) takes into account the National Institute for Health and Care Excellence (NICE) future work programme when considering whether a product will be appraised. To avoid duplication of effort, AWMSG would not normally consider undertaking an appraisal if NICE intend to publish final technology appraisal advice for the same product within twelve months of the projected Form B submission date. AWMSG advice is interim to that of NICE, should NICE subsequently publish guidance.

The above medicine cannot be endorsed for use within NHS Wales as a technology appraisal by NICE or AWMSG has not been undertaken. The medicine should NOT be prescribed routinely within NHS Wales for the indication stated above.

In the absence of guidance issued by NICE or AWMSG, clinicians should continue to exercise their clinical judgement when providing care for an individual patient. This should be in consultation with the patient and/or guardian or carer, based on the best available evidence.

This statement will be removed on receipt of a submission (i.e. the full submission [Forms A and B] or limited submission [Forms A and C]) or when final technology appraisal advice from NICE becomes available.